Breakdown of Bone Keeps Blood Sugar in Check, New Study Finds
NEW YORK (July 22, 2010) – Researchers led by Columbia University Medical Center have discovered that the skeleton plays an important role in regulating blood sugar and have further illuminated how bone controls this process. The finding, published in Cell, is important because it may lead to more targeted drugs for type 2 diabetes. Led by Gerard Karsenty, MD, PhD, chair of the Department of Genetics and Development at Columbia University Medical Center, the researchers found that the destruction of old bone during normal skeletal regrowth – a process known as resorption – is necessary to maintain a healthy level of glucose in the blood. While resorption is a process that occurs throughout life to make way for new bone, Dr. Karsenty’s team discovered that it also acts to stimulate the release of insulin into the bloodstream and improve the uptake of glucose by cells in the entire body. The findings suggest that, for some people, diabetes may develop from changes in the skeleton, and that drugs designed to stimulate the bone-insulin pathway may lead to better drugs for type 2 diabetes. The first clue that the skeleton may have an important role in regulating blood glucose came in 2007 when Dr. Karsenty discovered that a hormone released by bone – known as osteocalcin – can regulate glucose levels. Osteocalcin turns on the production of insulin in the pancreas and improves the ability of other cells to take in glucose. Both of these processes are impaired in type 2 diabetes. The new paper reveals that osteocalcin cannot work until cells that degrade bone start working and begin the resorption process. As the cells degrade bone, inactive osteocalcin is converted to its active form by the increase in acidity around the bone. “Remarkably, insulin was discovered to favor bone resorption. Hence, in a feed-forward loop it favors the activation of osteocalcin, which in turn favors insulin synthesis and secretion,” said Dr. Karsenty. “Insulin is a street-smart molecule that takes advantage of the functional interplay between bone resorption and osteocalcin, to turn-on the secretion and synthesis of more insulin.” By identifying the tight connection existing between energy metabolism and skeleton physiology – in this case between insulin and osteocalcin – this new study further underscores the wealth of physiological function exerted by the skeleton. The finding further strengthens the idea that diabetes could be treated by increasing the level of osteocalcin in the body. In addition, the researchers suggested that since most drugs to treat another condition – osteoporosis – work by inhibiting bone resorption, the drugs may decrease the activation of osteocalcin and cause glucose intolerance in some patients.
Insulin signaling in bone favors whole-body glucose homeostasis by activating osteocalcin. (1) Insulin signals osteoblasts, bone cells responsible for bone formation, which (2) tell osteoclasts, bone cells responsible for resorption, to destroy old bone. Next (3), the acidic (low pH) conditions created by the osteoclasts activates osteocalcin inside the bone. Finally (4), the active osteocalcin released from bone travels to the pancreas and stimulates the release of more insulin.
© Image provided by Columbia University Medical Center.
“This research has important implications for both diabetes and osteoporosis patients,” said Dr. Karsenty. “First, this research shows that osteocalcin is involved in diabetes onset; secondly, bone may become a new target in the treatment of type 2 diabetes, the most frequent form of diabetes, as it appears to contribute strongly to glucose intolerance; and, finally, osteocalcin could become a treatment for type 2 diabetes.” “And for people with osteoporosis, the concern is that a common treatment, bisphosphonates – which work by inhibiting bone resorption and therefore may increase glucose intolerance, could push someone with borderline glucose intolerance into full-fledged disease onset. Although, more research is needed to study this further,” said Dr. Karsenty. ### This work was supported by a fellowship from the Fond de la recherche en santé du Québec (M.F.) and grants from the National Institutes of Health (G.K.) and the Juvenile Diabetes Research Foundation (P.D.). Authors of the paper are: Mathieu Ferron1,5, Jianwen Wei1,5, Tatsuya Yoshizawa1,5, Andrea Del Fattore2, Ronald A. DePinho3, Anna Teti2, Patricia Ducy4 and Gerard Karsenty1* Affiliations: 1Department of Genetics & Development, and 4Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA; 2Department of Experimental Medicine, University of L’Aquila, L’Aquila, Italy; 3Department of Medicine and Genetics, Harvard Medical School, Boston, MA 02115, USA; 5These authors contributed equally and were placed in alphabetical order. Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia’s College of Physicians and Surgeons was the first institution in the country to grant the M.D. degree and is now among the most selective medical schools in the country. Columbia University Medical Center is home to the most comprehensive medical research enterprise in New York City and State and one of the largest in the United States. Columbia University Medical Center is affiliated with NewYork-Presbyterian Hospital, the nation’s largest not-for-profit, non-sectarian hospital provider. For more information, please visit www.cumc.columbia.edu.